Researchers Identify Bemnifosbuvir as Potential Treatment for Hepatitis E
An international team of researchers has identified bemnifosbuvir, a drug currently in trials for hepatitis C, as a promising candidate for treating hepatitis E. The study, published in the journal Gut, involved scientists from Bochum and Heidelberg in Germany and Beijing in China. Bemnifosbuvir belongs to a class of molecules known as nucleotide/nucleoside analogues, which mimic the building blocks of genetic material. The researchers tested approximately 500 compounds using a specially engineered hepatitis E virus that produces a fluorescent signal. This method allowed them to determine whether the virus continued to replicate after treatment. The results showed that bemnifosbuvir effectively stopped the virus from replicating while keeping the treated cells healthy. Follow-up studies in animals confirmed the drug's ability to reduce viral activity and liver inflammation. 
